Life Sciences Company Cambrex Invests $45 To $50 In Expansion Of Charles City, Iowa, Operations Hub
The Company expects to invest between $45 and $50 million during 2015, including a state of the art cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016 and is designed to allow Cambrex to quickly and efficiently further expand cGMP capacity, as future growth requires.
Shawn Cavanagh, Chief Operating Officer of Cambrex said, "In recent years, we have seen significantly stronger demand for the assets and capabilities that our Charles City facility has. We believe this expansion, combined with a very talented and experienced team, provides an ongoing foundation for our customers' small molecule product manufacturing needs and supports our goal of bringing our customers' products to market quickly."
According to company officials, “strong continued growth in demand for the Company's Active Pharmaceutical Ingredient contract manufacturing capabilities is driving the need for more capacity…We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.”
Joe Nettleton, VP of Operations of Cambrex Charles City said, "We are pleased to be expanding again so quickly in this competitive global pharmaceutical landscape. The need for increased API capacity comes on the back of strong market demand and high capacity utilization of our current large scale assets. There is high demand for US-based suppliers with large scale cGMP contract manufacturing capacity and world-class quality systems, and we have demonstrated that we are quite capable of meeting that demand."
The new manufacturing facility will initially add a total of 70 cubic meters of glass lined and hastelloy reactors ranging in size from 7m3 to 16m3 along with 6m2 hastelloy filter dryers to provide a flexible, multi-purpose configuration, company officials said. The facility will be designed to the highest regulatory and safety standards, capable of handling potent APIs at an OEL down to 1µg/m3 and will significantly increase the Company's cGMP manufacturing capabilities. The facility is also expandable with the ability to add additional capacity on a short timeline. The capacity is being added along with 45,000 square feet of new fully cGMP, temperature and humidity controlled warehouse space.
Vigilent Labs Plans $104.6 Million Headquarters & Operations Campus in North Charleston, South Carolina
Glock Manufacturer GS Performance Relocates Headquarters & Operations to Nashville, Tennessee
The New Normal in the Automotive Supply Chain
2020 Auto/Aero Site Guide
Why are Foreign Trade Zones Making a Comeback?
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Infrastructure Investment as an Economic Stimulus Tool
The Next Recovery: Regional Leaders & Laggards